UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000042941
Receipt number R000049016
Scientific Title Prospective study on the association between myocardial accumulation and heart disease in FDG PET for tumor diagnosis Myocardial Accumulation and Heart Disease in FDG PET for Tumor Diagnosis
Date of disclosure of the study information 2021/04/01
Last modified on 2021/02/25 11:44:14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study to clarify the relationship between FDG PET findings and heart disease for the purpose of tumor diagnosis

Acronym

Association between Tumor FDG PET Findings and Heart Disease

Scientific Title

Prospective study on the association between myocardial accumulation and heart disease in FDG PET for tumor diagnosis
Myocardial Accumulation and Heart Disease in FDG PET for Tumor Diagnosis

Scientific Title:Acronym

A Prospective Study on the Association between Tumor FDG PET Findings and Heart Disease

Region

Japan


Condition

Condition

Ischemic heart disease.

Classification by specialty

Psychosomatic Internal Medicine Radiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

There are many overlapping risk factors for carcinogenesis and ischemic heart disease, such as smoking and aging. The purpose of this study was to establish a screening method for heart disease using 18F-fluorodeoxyglucose Positron Emission Tomography (FDG PET), a nuclear medicine test for tumor diagnosis.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

To compare myocardial FDG accumulation patterns with the results of cardiac examinations to identify cardiac FDG accumulation patterns that are predictive of heart disease.

Key secondary outcomes

Myocardial FDG accumulation is known to be affected by fasting time and diet prior to FDG PET examination, and the optimal pre-test conditions will be discussed.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Device,equipment

Interventions/Control_1

Myocardial perfusion scintigraphy

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

60 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Men and women over 60 years old
(2) Scheduled to undergo FDG PET examination as a pre-treatment test for esophageal cancer or lung cancer.
(3) Have at least 3 of the following coronary risk factors (male, hypertension(systolic blood pressure >=130 mmHg), type 2 diabetes mellitus, hypertriglyceridemia (TG >=150 mg/dL), hypoHDLemia (HDL<40 mg/dL), smoking history, obesity (BMI>=25)).
(4) The contents of this study will be explained in writing and orally, and the subject will understand and give written consent.
(5) Good general health (PS2 or less)

Key exclusion criteria

(1) History of thoracic surgery or radiation to the chest
(2) Difficult to perform stress myocardial perfusion scintigraphy before treatment for esophageal cancer due to schedule
(3) Patients who are not eligible for PET scan or stress myocardial scintigraphy in their regular practice
Pregnancy and lactation: Pregnant and lactating women, or those who may be pregnant.
History of adverse reaction or allergy related to FDG administration in the past 18F-FDG-PET examination.
Prior history of adverse reactions or allergies related to drugs used in myocardial perfusion scintigraphy.
Treatment for unstable angina, complete atrioventricular block, or asthma
(4) Chest pain suggestive of angina pectoris.
(5) Previously indicated coronary artery stenosis of 90% or more by coronary CT and untreated
(6) Other conditions considered difficult to participate in the study
Difficulty in resting on a bed for 30 minutes
Inability to understand the content of the study due to psychosis or psychiatric symptoms
Patients who fall into any of the above categories are not eligible for the study.

Target sample size

300


Research contact person

Name of lead principal investigator

1st name Kentaro
Middle name
Last name takanami

Organization

Tohoku University Hospital

Division name

Department of Diagnostic Radiology

Zip code

980-8574

Address

Seiryo-cho 1-1, Aoba-ku, Sendai-city

TEL

022-717-7312

Email

takanami@rad.med.tohoku.ac.jp


Public contact

Name of contact person

1st name Mioko
Middle name
Last name Saito

Organization

Tohoku University Hospital

Division name

Department of Diagnostic Radiology

Zip code

980-8574

Address

Seiryo-cho 1-1, Aoba-ku, Sendai-city

TEL

022-717-7312

Homepage URL


Email

mioko.yoshida.b8@tohoku.ac.jp


Sponsor or person

Institute

Tohoku University

Institute

Department

Personal name



Funding Source

Organization

Japan Society for the Promotion of Science

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Tohoku University Hospital

Address

Seiryo-cho 1-1, Aoba-ku, Sendai City

Tel

022-717-3964

Email

ec@rinri.hosp.tohoku.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 04 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2021 Year 01 Month 07 Day

Date of IRB


Anticipated trial start date

2021 Year 04 Month 01 Day

Last follow-up date

2024 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 01 Month 07 Day

Last modified on

2021 Year 02 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049016


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name